Protagonist Therapeutics Return on Tangible Equity 2015-2022 | PTGX
Current and historical return on tangible equity values for Protagonist Therapeutics (PTGX) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Protagonist Therapeutics Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2022-03-31 |
$-0.12B |
$0.30B |
-38.17% |
| 2021-12-31 |
$-0.13B |
$0.30B |
-40.45% |
| 2021-09-30 |
$-0.11B |
$0.33B |
-35.24% |
| 2021-06-30 |
$-0.08B |
$0.36B |
-30.77% |
| 2021-03-31 |
$-0.07B |
$0.26B |
-31.96% |
| 2020-12-31 |
$-0.07B |
$0.28B |
-38.82% |
| 2020-09-30 |
$-0.07B |
$0.17B |
-54.17% |
| 2020-06-30 |
$-0.07B |
$0.17B |
-72.10% |
| 2020-03-31 |
$-0.08B |
$0.06B |
-103.11% |
| 2019-12-31 |
$-0.08B |
$0.08B |
-85.56% |
| 2019-09-30 |
$-0.07B |
$0.10B |
-74.30% |
| 2019-06-30 |
$-0.07B |
$0.08B |
-62.56% |
| 2019-03-31 |
$-0.05B |
$0.10B |
-41.26% |
| 2018-12-31 |
$-0.04B |
$0.11B |
-34.78% |
| 2018-09-30 |
$-0.03B |
$0.12B |
-24.79% |
| 2018-06-30 |
$-0.03B |
$0.11B |
-24.88% |
| 2018-03-31 |
$-0.03B |
$0.12B |
-34.93% |
| 2017-12-31 |
$-0.04B |
$0.12B |
-46.98% |
| 2017-09-30 |
$-0.05B |
$0.06B |
-63.83% |
| 2017-06-30 |
$-0.05B |
$0.06B |
-58.57% |
| 2017-03-31 |
$-0.04B |
$0.08B |
-72.90% |
| 2016-12-31 |
$-0.04B |
$0.09B |
-106.47% |
| 2016-06-30 |
$-0.02B |
$-0.05B |
191.30% |
| 2016-03-31 |
$-0.02B |
|
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.385B |
$0.027B |
|
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
|
